Tech support
Shopping Cart
Login
Register
Forgot Password?
Products
Diagnostics
Suppliers
About us
Contact
+31 (0)26 326 4450
Find the product you need
Description
Catalog number
CAS No.
Clone ID
News
Vorige
Volgende
InVivoPlus anti-mouse 4-1BB (CD137)
Catalog number:
BP0169_100mg
Brand:
Bio X Cell
Packing:
100 mg
Other sizes:
Other sizes available
Price:
€ 4062.00
Expected delivery time:
7 days
Quantity:
Spin Up
Spin Down
General
References
Product specifications for - InVivoPlus anti-mouse 4-1BB (CD137)
Promotion:
Promotion:
The price displayed is only for academic or non-profit organizations. Please
contact our helpdesk
for regular prices.
Overview:
Product group:
Antibodies
Category:
Primary Antibodies
Application:
Other Application
Host:
Rat
Clonality:
Monoclonal
Isotype:
IgG2a
Properties:
Molecular weight:
150 kDa
Datasheet:
Datasheet
Research Use Only
UNSPSC:
12352203
Concentration:
2-10 mg/ml
Scientific information:
Clone ID:
LOB12.3
Related products:
Related products:
Recommended Isotype Control(s):
InVivoPlus rat IgG2a isotype control (BP0089)
Recommended Dilution Buffer:
InVivoPure pH 8.0 Dilution Buffer (IP0080)
Additional information:
Synonyms:
LOB12.3; BP0169; BioXCell
Bartkowiak T, Singh S, Yang G, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci USA. 2015;112(38):E5290-9.
Read more
Dai M, Yip YY, Hellstrom I, Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015;21(5):1127-38.
Read more
Murphy JT, Burey AP, Beebe AM, et al. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood. 2014;123(14):2172-80.
Read more
Wei H, Zhao L, Li W, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS ONE. 2013;8(12):e84927.
Read more
Guo Z, Cheng D, Xia Z, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med. 2013;11:215.
Read more
Dai M, Wei H, Yip YY, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother. 2013;36(4):248-57.
Read more
Manzke N, Akhmetzyanova I, Hasenkrug KJ, Trilling M, Zelinskyy G, Dittmer U. CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells. J Virol. 2013;87(11):6306-13.
Read more
Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013;73(5):1547-58.
Read more
Curran MA, Kim M, Montalvo W, Al-shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS ONE. 2011;6(4):e19499.
Read more
Taraban VY, Rowley TF, O'brien L, et al. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol. 2002;32(12):3617-27.
Read more
See All